Lilly Diabetes Center of Excellence

Robert Considine, PhD
Indiana Biosciences Research Institute
1345 W. 16 th St. Suite 300
Indianapolis, IN 46202
rconsidine@indianabiosciences.org

Office: 317-983- 3350
Lab: 317-983- 3350

Research Summary

IBRI DIABETES CENTER (IDC) - LILLY DIABETES CENTER OF EXCELLENCE

Focus: Cutting-edge diabetes research

With the establishment in the fall of 2018 of the Lilly Diabetes Center of Excellence (LDCE), a collaboration between Eli Lilly and Company, Indiana University (IU) School of Medicine and the IBRI, the LDCE became the research core of the IBRI Diabetes Center.

The LDCE aims to become a nexus of strategically aligned basic diabetes research in central Indiana by recruiting promising and established principal investigators (PIs) who will pursue cutting-edge research in diabetes, diabetic complications and related metabolic disorders.

The PIs will have five-year sponsored appointments at the IBRI, subsidized by Lilly, as well as faculty appointments at the IU School of Medicine. Each PI will pursue their area of research with full academic freedom. Lilly is providing opportunities for close collaboration, including access to drug discovery tools and expertise, allowing faculty to rapidly explore the translational potential of their research. The LDCE will also serve as a bridge between academia and industry by providing opportunities for interaction, training and mentoring across the IBRI, Lilly and IU School of Medicine. 

 

Lab Team

Robert Considine

Robert Considine, PhD

Professor of Medicine, Director, IBRI Diabetes Center

Robert Considine

Robert Considine, PhD

Professor of Medicine, Director, IBRI Diabetes Center

Robert V. Considine, Ph.D., joined the Division of Endocrinology at the Indiana University School of Medicine in Indianapolis, Ind., as an Assistant Professor in 1997 and was promoted to Professor in 2013. Prior to his appointment at the IU School of Medicine, he was on the faculty of the Department of Medicine at Thomas Jefferson University in Philadelphia, Pa., where he had completed his doctoral training.

Dr. Considine’s research is focused on understanding the contribution of obesity to the development of diabetes and its complications. In early work, his lab made seminal observations about the function of the adipose tissue hormone leptin in humans.  More recently, the Considine lab has focused on the effects of bariatric surgery to alter gut hormone release and improve glucose homeostasis and insulin sensitivity.  In collaboration with David Kareken, Ph.D., at the IU School of Medicine, Dr. Considine is also utilizing neuroimaging techniques to understand the reward system response to food cues in human subjects.  

Dr. Considine is currently the Associate Director of the National Institutes of Health (NIH)-funded Diabetes Center at the IU School of Medicine, and oversees the Analyte Laboratory, which provides quantitation of adipokines, cytokines, gut peptides and hormones from human and animal samples.  He is also the Statewide Director for Endocrine and Reproductive Biology, a second-year course in the IU School of Medicine curriculum.